Back to User profile » Dr Thomas Goodin
Papers published by Dr Thomas Goodin:
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1347-1348
Published Date: 14 May 2021
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
Hanania NA, Yohannes AM, Ozol-Godfrey A, Tocco M, Goodin T, Sharma S, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:865-875
Published Date: 31 March 2021
The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
Donohue JF, Ozol-Godfrey A, Goodin T, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1177-1178
Published Date: 26 May 2020
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:995-1004
Published Date: 6 May 2020
The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
Donohue JF, Ozol-Godfrey A, Goodin T, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:745-754
Published Date: 14 April 2020
Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of the GEM1 and GEM2 12-week studies
Ohar JA, Bowling A, Goodin T, Price B, Ozol-Godfrey A, Sharma S, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:461-470
Published Date: 19 February 2019
Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
Ohar J, Tosiello R, Goodin T, Sanjar S
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:27-37
Published Date: 18 December 2018
Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
Kerwin EM, Tosiello R, Price B, Sanjar S, Goodin T
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2917-2929
Published Date: 19 September 2018